Torrent Pharma has today announced that it is introducing MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback’s molnupiravir under the brand name Molnutor® in India. Earlier this year, Torrent Pharma inked a non-exclusive voluntary licensing pact with MSD, granting rights to Torrent Pharma for manufacturing, distribution and marketing of Molnupiravir in more than 100 low-and middle-income markets including India for treatment of COVID-19.
The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir has approved the drug for the treatment of COVID-19 in adults for restricted emergency use in India.
Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and U.S. Food and Drug Administration (FDA) [for Emergency Use Authorisation (EUA)] for the treatment of mild-to-moderate COVID -19 in adults.
Commenting on the launch, Aman Mehta (Executive Director – India) said: “We are pleased to partner with MSD to bring Molnupiravir to patients across India. Molnupiravir will be an important addition to our healthcare system’s ammunition in the fight against Covid-19.”
Torrent Pharmaceuticals Ltd: Torrent Pharma, with annual revenues of more than Rs 8,000 crores, is the flagship Company of the Torrent Group, with group revenues of more than Rs 20,000 crores. It is ranked 8th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Central Nervous System (CNS), and Vitamins Minerals Nutritionals (VMN).
It is a specialty-focused company with 75%+ of its revenue in India from chronic & sub-chronic therapies. It has presence in 40 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines. Torrent has 8 manufacturing facilities (7 in India & 1 in US), of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 750+ scientists.
About Author
